WEISLER DION J 4

What Happened

• Dion J. Weisler, a member of the Board of Directors of Thermo Fisher Scientific (TMO), was credited with 79.22 deferred stock units on March 28, 2026. The Form 4 lists the transaction as an award/acquisition (derivative) and reports the per‑unit valuation at $473.36, implying a total value of roughly $37,500.
• This was an award of deferred compensation (stock units), not an open‑market purchase or sale. The units are convertible 1‑for‑1 into common stock and will be distributable as shares upon cessation of director service or a change of control.

Key Details

• Transaction date: March 28, 2026; Form 4 filed March 31, 2026 (no late filing indicated).
• Reported units: 79.22 deferred stock units; per‑unit price cited in footnote: $473.36; implied total ≈ $37,500.
• Transaction type: Award/Grant (derivative), convertible into common stock on a 1-for-1 basis (Footnotes F1, F2).
• These units were credited under the Issuer’s Deferred Compensation Plan for Directors (directors’ retainers deferred quarterly as stock units).
• Shares owned after the transaction: Not specified in the supplied filing details.

Context

• Deferred stock units are a form of compensation that convert into shares under plan terms; they are routine director compensation and do not represent a market buy/sell signal by themselves.
• Because this is an award (not a purchase or sale), it should be interpreted as part of standard director pay rather than an overt expression of bullish or bearish sentiment.